Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.
Luckily for you, we at StockStory have no conflicts of interest - our sole job is to help you find genuinely promising companies. That said, here are two stocks where Wall Street’s positive outlook is supported by strong fundamentals and one where consensus estimates seem disconnected from reality.
One Stock to Sell:
Utz (UTZ)
Consensus Price Target: $17.25 (31.2% implied return)
Tracing its roots back to 1921 when Bill and Salie Utz began making potato chips in their kitchen, Utz Brands (NYSE: UTZ) offers salty snacks such as potato chips, tortilla chips, pretzels, cheese snacks, and ready-to-eat popcorn, among others.
Why Are We Out on UTZ?
- Organic revenue growth fell short of our benchmarks over the past two years and implies it may need to improve its products, pricing, or go-to-market strategy
- Revenue base of $1.41 billion puts it at a disadvantage compared to larger competitors exhibiting economies of scale
- Below-average returns on capital indicate management struggled to find compelling investment opportunities
At $13.15 per share, Utz trades at 15.1x forward P/E. Dive into our free research report to see why there are better opportunities than UTZ.
Two Stocks to Watch:
Humana (HUM)
Consensus Price Target: $298.53 (26.6% implied return)
With over 80% of its revenue derived from federal government contracts, Humana (NYSE: HUM) provides health insurance plans and healthcare services to approximately 17 million members, with a strong focus on Medicare Advantage plans for seniors.
Why Are We Fans of HUM?
- Offerings and unique value proposition resonate with customers, as seen in its above-market 12.2% annual sales growth over the last five years
- Massive revenue base of $120.2 billion gives it meaningful leverage when negotiating reimbursement rates
- Projected revenue growth of 6% for the next 12 months suggests its momentum from the last two years will persist
Humana’s stock price of $235.90 implies a valuation ratio of 15.8x forward P/E. Is now the right time to buy? See for yourself in our comprehensive research report, it’s free.
Rumble (RUM)
Consensus Price Target: $15 (69.1% implied return)
Founded in 2013 as a champion for content creator rights and free expression, Rumble (NASDAQ: RUM) is a video sharing platform that positions itself as a free speech alternative to mainstream platforms, offering creators more favorable revenue-sharing opportunities.
Why Do We Like RUM?
- Annual revenue growth of 38.4% over the past two years was outstanding, reflecting market share gains this cycle
Rumble is trading at $8.87 per share, or 21.3x trailing 12-month price-to-sales. Is now a good time to buy? Find out in our full research report, it’s free.
High-Quality Stocks for All Market Conditions
Market indices reached historic highs following Donald Trump’s presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth.
While this has caused many investors to adopt a "fearful" wait-and-see approach, we’re leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today for free. Find your next big winner with StockStory today. Find your next big winner with StockStory today
